Objective: Stroke, following heart disease and cancer, is the third most common cause of mortality and is the most common cause of morbidity in the world. The enzyme methylenetetrahydrofolate reductase (MTHFR) plays a critical role in modulating the levels of plasma homocysteine. Hyperhomocysteinemia is a risk factor for stroke. The polymorphysm in the methylenetetrahydrofolate reductase gene C677T results in reduced enzyme activity. This study was performed to observe the rate of MTHFR C677T genetic polymorphysm and its effect to hyperhomocysteinemia as a risk factor.